ALPCO, a leading producer of research and clinical immunoassays, provides an FDA Class I Exempt Pancreatic Elastase ELISA that can reliably measure PE-1 and, in turn, help laboratories save valuable resources.
WARMINSTER, Pa. — Abraxis, Inc., which develops, manufactures, and markets rapid environmental and food test systems in plate, strip test, and magnetic bead formats, announces two new additions to its AbraMag® Magnetic Beads line: ◦DNA Fragment Size Selection ◦PCR Clean-Up
ALPCO, a leading producer of research and clinical immunoassays, announced it will feature its therapeutic drug monitoring (TDM) ELISA portfolio at the AACC’s 70th Clinical Lab Expo July 31-August 2 in Chicago.
Aim Lab’s PathFinder 350A Archiver is a compact bench top workstation for automating the capping (foil sealing), sorting and archiving of sample tubes directly from analyzer racks into low cost storage racks. When sampling is complete, analyzer racks are loaded onto the PathFinder 350A for processing. Those sample tubes where all requested tests have been completed are foil sealed and sorted into uniquely identified storage racks. Tubes are capped with a laminated foil which seals the tube preventing evaporation and leakage during transport or freezer storage.
The American Chiropractic Association has endorsed the Casper Wave mattress.
XaTek Inc., a Cleveland-based company developing a portable sensing system that can quickly assess the clotting ability of a person’s blood, recently raised $9.1 million in Series A capital to further advance and test the device, called ClotChip.
Adaltis and ISE will be launching their new clinical chemistry analyser HemoOne™ at the 70th AACC meeting in Chicago in July 2018.
On stand 352 at AACC 2018, Carville will be showing the latest technology in diffusion bonded, multi-layer plastic fluidic manifolds including microfluidics.
Nine health-tech companies have joined the newest class of the Cedars-Sinai Accelerator as they look to develop and refine solutions to some of healthcare's most pressing challenges, particularly those affecting the experience of patients. The companies will receive an initial investment of $120,000, training from Cedars-Sinai physicians and executives, and exposure to a global entrepreneurial network through Techstars, an organization that works with entrepreneurs to cultivate their ideas.
With “SYIONS”, Jenoptik is broadening its extensive expertise in diagnostics and analytics solutions to include a digital image capture, processing and analysis platform that can be configured to the customer’s specific needs. Premiere at SPIE BiOS and SPIE Photonics West in San Francisco.
St. Louis, May 14, 2018 BacterioScan, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a 510(k) Premarket Notification clearance for its 216Dx Urinary Tract Infection (UTI) detection system. The BacterioScan 216Dx system is a rapid automated diagnostic system for the detection of bacterial UTIs, one of the most common types of infection.
The Genie and Super-Genie are the new generation of laboratory water purification systems from RephiLe.
Fuzhou XinBei Biochemical Industrial Co. Ltd is a company that develops and manufactures Tachypleus Amebocyte Lysate(TAL) as well as related TAL accessory products.
Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors.
B-Line Medical, an industry leader in video-driven healthcare education and outcome improvement, is excited to announce a continued partnership with St. George’s University as it expands and upgrades its healthcare simulation center.
Blood grouping/ reverse grouping/ phenotyping/ crossmatching/ antibody screening/ antibody identification/ direct AHG test(DAT)/ single antigens/Rh(D) Rh(CcEe)/Newborn-ABO-Rh/ Rh/k/ ABO DD/Kell/ AHG Polyspecific/ ADK
UCP Biosciences, Inc.—a leading supplier of In Vitro Diagnostics (IVD)—offers top notch Point of Care Testing (POCT) devices ranging from instant urine and saliva drug tests (in the U.S. Market) to Infectious Disease, Women’s Health, Cardiac Markers, and Tumor Markers (in the International Market).
Baebies, a growth-stage company that delivers innovative products and services for newborn screening and pediatric testing, today announced that it has secured $10 million in Series B financing in an oversubscribed round anchored by BOE Technology Group Co., Ltd.
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced today it has received de novo clearance from the U.S. Food and Drug Administration (FDA) for SEEKER. SEEKER quantitatively measures the activity of lysosomal enzymes α-L-iduronidase (IDUA), α-D-glucosidase (GAA), β-glucocerebrosidase (GBA) and α-D-galactosidase A (GLA) from newborn dried blood spot specimens. Reduced activity of these enzymes may be indicative of lysosomal storage diseases (LSDs) Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry, respectively.
Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced the first assays on the FINDER launch panel, currently under development. The panel includes tests for total serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase (G6PD) on a single cartridge, making it the first comprehensive, rapid and near-patient testing solution for hyperbilirubinemia. A robust pipeline of future panels for other disorders using the same cartridge on FINDER is also in development.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right